Literature DB >> 14659975

Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas.

Kazuhiro Takekoshi1, Kazumasa Isobe, Tohru Yashiro, Hisato Hara, Kiyoaki Ishii, Yasushi Kawakami, Toshiaki Nakai, Yukichi Okuda.   

Abstract

Pheochromocytomas are well-vascularized tumors, suggesting that a potent angiogenic factor may be involved in the mechanism of their formation. As vascular endothelial growth factor (VEGF) is a potent mitogen for vascular endothelial cells, here we have investigated the mRNA and protein expression of VEGF and the mRNA expression of its two receptors (Flt-1 and Flk-1/KDR) in pheochromocytomas tissue. An increase in VEGF mRNA (mainly isoforms VEGF(121) and VEGF(165)) and in VEGF protein expression were observed by semi-quantitative RT-PCR and Western blot, respectively, compared to normal adrenomedullary tissue. Flk-1/KDR, and Flt-1 levels of mRNA were also increased markedly in tumors and correlated with levels of VEGF mRNA. Therefore, we speculate that upregulation of VEGF expression and its receptors might be important in the pathogenesis of pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14659975     DOI: 10.1016/j.lfs.2003.07.036

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  15 in total

1.  Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.

Authors:  Judith Favier; Peter Igaz; Nelly Burnichon; Laurence Amar; Rossella Libé; Cécile Badoual; Frédérique Tissier; Jérôme Bertherat; Pierre-François Plouin; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

2.  Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.

Authors:  Hamidreza Aliabadi; James J Vredenburgh; Richard G Everson; Annick Desjardins; Henry S Friedman; Roger E McLendon; Debara L Tucci; John H Sampson
Journal:  J Neurooncol       Date:  2009-12-19       Impact factor: 4.130

Review 3.  Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.

Authors:  Camilo Jimenez; Eric Rohren; Mouhammed Amir Habra; Thereasa Rich; Paola Jimenez; Montserrat Ayala-Ramirez; Eric Baudin
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

4.  Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.

Authors:  Uma Shankavaram; Stephanie M J Fliedner; Abdel G Elkahloun; Jenifer J Barb; Peter J Munson; Thanh T Huynh; Joey C Matro; Hana Turkova; W Marston Linehan; Henri J Timmers; Arthur S Tischler; James F Powers; Ronald de Krijger; Bora E Baysal; Martina Takacova; Silvia Pastorekova; David Gius; Hendrik Lehnert; Kevin Camphausen; Karel Pacak
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

5.  The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism.

Authors:  Hengchuan Su; Yanyun Gu; Fengying Li; Qidi Wang; Baoxing Huang; Xiaolong Jin; Guang Ning; Fukang Sun
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

6.  Assessment of control tissue for gene and protein expression studies: a comparison of three alternative lung sources.

Authors:  Margaret R Passmore; Maria Nataatmadja; John F Fraser
Journal:  ScientificWorldJournal       Date:  2012-04-19

Review 7.  Target therapy in metastatic pheochromocytoma: current perspectives and controversies.

Authors:  Amrallah A Mohammed; Ayman M El-Shentenawy; Mohamed A Sherisher; Hani M El-Khatib
Journal:  Oncol Rev       Date:  2014-09-23

8.  Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.

Authors:  Gabriele Parenti; Benedetta Zampetti; Elena Rapizzi; Tonino Ercolino; Valentino Giachè; Massimo Mannelli
Journal:  J Oncol       Date:  2012-07-17       Impact factor: 4.375

9.  Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations.

Authors:  D J Pinato; R Ramachandran; S T K Toussi; M Vergine; N Ngo; R Sharma; T Lloyd; K Meeran; F Palazzo; N Martin; B Khoo; R Dina; T M Tan
Journal:  Br J Cancer       Date:  2012-12-20       Impact factor: 7.640

10.  Reduction of splenic immunosuppressive cells and enhancement of anti-tumor immunity by synergy of fish oil and selenium yeast.

Authors:  Hang Wang; Yi-Lin Chan; Tsung-Lin Li; Brent A Bauer; Simon Hsia; Cheng-Hsu Wang; Jen-Seng Huang; Hung-Ming Wang; Kun-Yun Yeh; Tse-Hung Huang; Gwo-Jang Wu; Chang-Jer Wu
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.